The sites participating in the first stage of the POET-2 clinical trial program are: 1) University of Alabama, Birmingham, AL, Principal Investigator: Ray Watts, M.D.; 2) University of Arizona Medical Center, Tucson, AZ, Principal Investigator: Scott Sherman, M.D.; 3) Cedars-Sinai Medical Center, Los Angeles, CA, Principal Investigator: Alan Waxman, M.D.; 4) University of Florida McKnight Brain Institute, Gainesville, FL, Principal Investigator: Ramon Rodriguez, M.D.; 5) Dartmouth-Hitchcock Medical Center, Lebanon, NH, Principal Investigator: David Coffey, M.D.; 6) University of Texas Houston Medical School, Houston, TX, Principal Investigator: Mya Schiess, M.D.; 7) University of Texas Southwestern Medical Center, Dallas, TX, Principal Investigator: Padraig O'Suilleabhain, M.D.
"We continue to be optimistic about the diagnostic value that ALTROPANE may represent to those with undiagnosed tremor," commented Dr. Alan Waxman of Cedars Sinai Medical Center, a nuclear-medicine expert, a professor at the University of Southern California, and a principal investigator in the ALTROPANE trial. "As an imaging center, we are pleased with ALTROPANE's high quality scans and rapid imaging process which benefits both the patient and the clinic."
The Tremor Action Network estimates that as many as 10 million people
in the United States are afflicted by essential tremor. Experts estimate
that, each year, approximately 140,000 individuals present to their
physician with new, undiagnosed movement disorders such as Parkinson's
Disease and Essential Tremor. In 2002, the European Journal of Neurology
reported that there is a 20- to 30-percent misdiagnosis rate in the early
stages of Parkinson's disease. Other publications have reported even higher
rates of misdiagnosis. The accurate differentiation of Parkinsonian from
non-Parkinsonian tremors could allow physicians to initiate earlier
referral for specialty care, prescribe effectiv
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved